Search

Your search keyword '"Wobser, M."' showing total 224 results
Start Over Author "Wobser, M."
224 results on '"Wobser, M."'

1. Evaluation of Sézary cell marker expression and cell death behaviour upon in vitro treatment by flow cytometry in Sézary syndrome patients.

Author

Melchers, S., Roemer, M., Albrecht, J. D., Assaf, C., von Gugelberg, C., Guenova, E., Klemke, C.‐D., Moritz, R. K. C., Schlaak, M., Stadler, R., Wehkamp, U., Wobser, M., Albrecht, T., Goerdt, S., Schneider, S., and Nicolay, J. P.

Subjects
MONONUCLEAR leukocytes, CELL death, DIMETHYL fumarate, CELL populations, CELL analysis
Abstract

The diagnosis of Sézary syndrome (SS) relies on the identification of blood Sézary cells (SC) by different markers via flow cytometry. Treatment of SS is challenging since its pathogenesis is characterized by cell death resistance rather than hyperproliferation. In this study, we establish an integrated approach that considers both the expression of SC markers and sensitivity to cell death both spontaneously and upon in vitro treatment. Peripheral blood mononuclear cells were isolated from 20 SS patients and analysed for the SC markers CD7 and CD26 loss as well as CD158k and PD1 gain. The cells were then treated with different established and experimental therapies in vitro and cell death was measured. Spontaneous and therapeutically induced cell death were measured and correlated to cellular marker profiles. In the marker‐positive cells, spontaneous cell death sensitivity was reduced. Different treatments in vitro managed to specifically induce cell death in the putative CTCL cell populations. Interestingly, a repeated analysis after 3 months of treatment revealed the CTCL cell death sensitivity to be restored by therapy. We propose this novel integrated approach comprising the evaluation of SC marker expression and analysis of cell death sensitivity upon treatment that can also enable a better therapy stratification. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Health- related quality of life and its influencing factors in patients with primary cutaneous B- cell lymphomas: A multicentric study in 100 patients.

Author

Schirren, A. E. C., Albrecht, J. D., Melchers, S., Weiß, C., Büttner, S., Dippel, E., Gosmann, J., Jonak, C., Klemke, C.-D., Laturnus-Chang, M., Livingstone, E., Mitteldorf, C., Schummer, P., Stadler, R., Stranzenbach, R., Weyer-Fahlbusch, S. S., Wobser, M., Ziemer, M., and Nicolay, J. P.

Subjects
CUTANEOUS T-cell lymphoma, QUALITY of life, MUCOSA-associated lymphoid tissue lymphoma, MULTIPLE regression analysis, LYMPHOMAS, WATCHFUL waiting
Abstract

Background: Primary cutaneous B-cell lymphomas (CBCL) are a group of rare malignant skin diseases that represent approximately 20%--30% of all primary cutaneous lymphomas (PCL). Previous studies revealed impaired health-related quality of life (HRQoL) in patients diagnosed with primary cutaneous T-cell lymphoma (CTCL). Currently, only small-sized studies investigated HRQoL in CBCL patients and lacked detailed analysis of respective subtypes. Objectives: This study aims to investigate HRQoL in CBCL patients to identify independent factors of HRQoL impairment in CBCL patients. Methods: One hundred CBCL patients were recruited from eight German PCL centres in this multicentric, cross-sectional study from 2021 to 2022. The patients completed the dermatologic HRQoL questionnaire Skindex-29 and an investigator-designed 'CBCL-Questionnaire' with additional questions on HRQoL and clinical characteristics. Results: The Skindex-29 revealed that HRQoL in CBCL patients is impaired on a mild to moderate level. The multiple regression analysis identified parameters like worries about dying, feeling prejudiced/discriminated and impairment of daily activities to be independently associated with impairment of HRQoL. Highest scores for HRQoL impairment were found in patients with primary cutaneous follicle centre lymphoma while on rituximab treatment and in patients with primary cutaneous marginal zone lymphoma while on watchful waiting. Conclusions: HRQoL is impaired in CBCL patients, even though, in the face of indolent disease course and favourable prognosis in the majority of cases. Of note, our investigator-designed tool identified worries about dying, feeling prejudiced/discriminated, and the type of treatment to have a negative impact on patients' HRQoL. Our study highlights the importance of a thorough patient--doctor communication to capture overall disease burden because generic HRQoL tools might lack of disease-specific items. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomas

Author

Schirren, AEC, primary, Albrecht, JD, additional, Dippel, E, additional, Fahlbusch, S, additional, Gosmann, J, additional, Klemke, CD, additional, Chang, M Laturnus, additional, Livingstone, E, additional, Mitteldorf, C, additional, Schummer, P, additional, Stadler, R, additional, Stranzenbach, R, additional, Wobser, M, additional, Ziemer, M, additional, and Nicolay, JP, additional

Published
2022
Full Text
View/download PDF

7. Should we be imaging lymph nodes at initial diagnosis of early‐stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*

Author

Hodak, E., Sherman, S., Papadavid, E., Bagot, M., Querfeld, C., Quaglino, P., Prince, H.M., Ortiz-Romero, P.L., Stadler, R., Knobler, R., Guenova, E., Estrach, T., Patsatsi, A., Leshem, Y.A., Prague-Naveh, H., Berti, E., Alberti-Violetti, S., Cowan, R., Jonak, C., Nikolaou, V., Mitteldorf, C., Akilov, O., Geskin, L., Matin, R., Beylot-Barry, M., Vakeva, L., Sanches, J.A., Servitje, O., Weatherhead, S., Wobser, M., Yoo, J., Bayne, M., Bates, A., Dunnill, G., Marschalko, M., Buschots, A.M., Wehkamp, U., Evison, F., Hong, E., Amitay-Laish, I., Stranzenbach, R., Vermeer, M., Willemze, R., Kempf, W., Cerroni, L., Whittaker, S., Kim, Y.H., Scarisbrick, J.J., Cutaneous Lymphoma Int Consortium, HUS Inflammation Center, Clinicum, and Helsinki University Hospital Area

Subjects
medicine.medical_specialty, Skin Neoplasms, EUROPEAN-ORGANIZATION, SOCIETY, Physical examination, Dermatology, GUIDELINES, CLASSIFICATION, Cutaneous lymphoma, Cutaneous patch, 030207 dermatology & venereal diseases, 03 medical and health sciences, Mycosis Fungoides, 0302 clinical medicine, International Prognostic Index, Biopsy, SEZARY-SYNDROME, medicine, Humans, COMPUTED-TOMOGRAPHY, Prospective Studies, Stage (cooking), RESPONSE CRITERIA, Neoplasm Staging, Body surface area, Mycosis fungoides, medicine.diagnostic_test, business.industry, CONSORTIUM, Prognosis, medicine.disease, 3121 General medicine, internal medicine and other clinical medicine, SURVIVAL, Lymph Nodes, Radiology, business, TASK-FORCE
Abstract

Background Early-stage mycosis fungoides (MF) includes involvement of dermatopathic lymph nodes (LNs) or early lymphomatous LNs. There is a lack of unanimity among current guidelines regarding the indications for initial staging imaging in early-stage presentation of MF in the absence of enlarged palpable LNs. Objectives To investigate how often imaging is performed in patients with early-stage presentation of MF, to assess the yield of LN imaging, and to determine what disease characteristics promoted imaging. Methods A review of clinicopathologically confirmed newly diagnosed patients with cutaneous patch/plaque (T1/T2) MF from PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) data. Results PROCLIPI enrolled 375 patients with stage T1/T2 MF: 304 with classical MF and 71 with folliculotropic MF. Imaging was performed in 169 patients (45%): 83 with computed tomography, 18 with positron emission tomography-computed tomography and 68 with ultrasound. Only nine of these (5%) had palpable enlarged (>= 15 mm) LNs, with an over-representation of plaques, irrespectively of the 10% body surface area cutoff that distinguishes T1 from T2. Folliculotropic MF was not more frequently imaged than classical MF. Radiologically enlarged LNs (>= 15 mm) were detected in 30 patients (18%); only seven had clinical lymphadenopathy. On multivariate analysis, plaque presentation was the sole parameter significantly associated with radiologically enlarged LNs. Imaging of only clinically enlarged LNs upstaged 4% of patients (seven of 169) to at least IIA, whereas nonselective imaging upstaged another 14% (24 of 169). LN biopsy, performed in eight of 30 patients, identified N3 (extensive lymphomatous involvement) in two and N1 (dermatopathic changes) in six. Conclusions Physical examination was a poor determinant of LN enlargement or involvement. Presence of plaques was associated with a significant increase in identification of enlarged or involved LNs in patients with early-stage presentation of MF, which may be important when deciding who to image. Imaging increases the detection rate of stage IIA MF, and identifies rare cases of extensive lymphomatous nodes, upstaging them to advanced-stage IVA2.

Published
2020
Full Text
View/download PDF

8. Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop*

Author

Kempf, W., Petrella, T., Willemze, R., Jansen, P., Berti, E., Santucci, M., Geissinger, E., Cerroni, L., Maubec, E., Battistella, M., Goodlad, J., Guenova, E., Lappalainen, K., Ranki, A., Craig, P., Calonje, E., Martin, B., Whittaker, S., Oschlies, I., Wehkamp, U., Nicolay, J. P., Wobser, M., Scarisbruck, J., Pimpinelli, N., Stadler, R., Kerl French, K., Quaglino, P., Lin, J., Chen, L., Beer, M., Emanuel, P., Dalle, S., and Robson, A.

Subjects
Cutaneous, Skin Neoplasms, Lymphoma, CD8-Positive T-Lymphocytes, Humans, Prognosis, Retrospective Studies, Lymphoma, T-Cell, Cutaneous, T-Cell
Published
2022

15. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study

Author

Hodak, E. Sherman, S. Papadavid, E. Bagot, M. Querfeld, C. Quaglino, P. Prince, H. M. Ortiz-Romero, P. L. and Stadler, R. Knobler, R. Guenova, E. Estrach, T. and Patsatsi, A. Leshem, Y. A. Prague-Naveh, H. Berti, E. and Alberti-Violetti, S. Cowan, R. Jonak, C. Nikolaou, V and Mitteldorf, C. Akilov, O. Geskin, L. Matin, R. and Beylot-Barry, M. Vakeva, L. Sanches, J. A. Servitje, O. and Weatherhead, S. Wobser, M. Yoo, J. Bayne, M. Bates, A. and Dunnill, G. Marschalko, M. Buschots, A. M. Wehkamp, U. and Evison, F. Hong, E. Amitay-Laish, I Stranzenbach, R. and Vermeer, M. Willemze, R. Kempf, W. Cerroni, L. and Whittaker, S. Kim, Y. H. Scarisbrick, J. J. Cutaneous Lymphoma Int Consortium

Abstract

Background Early-stage mycosis fungoides (MF) includes involvement of dermatopathic lymph nodes (LNs) or early lymphomatous LNs. There is a lack of unanimity among current guidelines regarding the indications for initial staging imaging in early-stage presentation of MF in the absence of enlarged palpable LNs. Objectives To investigate how often imaging is performed in patients with early-stage presentation of MF, to assess the yield of LN imaging, and to determine what disease characteristics promoted imaging. Methods A review of clinicopathologically confirmed newly diagnosed patients with cutaneous patch/plaque (T1/T2) MF from PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) data. Results PROCLIPI enrolled 375 patients with stage T1/T2 MF: 304 with classical MF and 71 with folliculotropic MF. Imaging was performed in 169 patients (45%): 83 with computed tomography, 18 with positron emission tomography-computed tomography and 68 with ultrasound. Only nine of these (5%) had palpable enlarged (>= 15 mm) LNs, with an over-representation of plaques, irrespectively of the 10% body surface area cutoff that distinguishes T1 from T2. Folliculotropic MF was not more frequently imaged than classical MF. Radiologically enlarged LNs (>= 15 mm) were detected in 30 patients (18%); only seven had clinical lymphadenopathy. On multivariate analysis, plaque presentation was the sole parameter significantly associated with radiologically enlarged LNs. Imaging of only clinically enlarged LNs upstaged 4% of patients (seven of 169) to at least IIA, whereas nonselective imaging upstaged another 14% (24 of 169). LN biopsy, performed in eight of 30 patients, identified N3 (extensive lymphomatous involvement) in two and N1 (dermatopathic changes) in six. Conclusions Physical examination was a poor determinant of LN enlargement or involvement. Presence of plaques was associated with a significant increase in identification of enlarged or involved LNs in patients with early-stage presentation of MF, which may be important when deciding who to image. Imaging increases the detection rate of stage IIA MF, and identifies rare cases of extensive lymphomatous nodes, upstaging them to advanced-stage IVA2.

Published
2021

16. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study

Author

Quaglino, P. Prince, H. M. Cowan, R. Vermeer, M. and Papadavid, E. Bagot, M. Servitjie, O. Berti, E. Guenova, E. Stadler, R. Querfeld, C. Busschots, A. M. Hodak, E. and Patsatsi, A. Sanches, J. Maule, M. Yoo, J. Kevin, M. and Fava, P. Ribero, S. Zocchi, L. Rubatto, M. Fierro, M. T. Wehkamp, U. Marshalko, M. Mitteldorf, C. Akilov, O. Ortiz-Romero, P. Estrach, T. Vakeva, L. Enz, P. A. and Wobser, M. Bayne, M. Jonak, C. Rubeta, M. Forbes, A. and Bates, A. Battistella, M. Amel-Kashipaz, R. Vydianath, B. Combalia, A. Georgiou, E. Hauben, E. Hong, E. K. and Jost, M. Knobler, R. Amitay-Laish, I. Miyashiro, D. and Cury-Martins, J. Martinez, X. Muniesa, C. Prag-Naveh, H. and Stratigos, A. Nikolaou, V. Quint, K. Ram-Wolff, C. and Rieger, K. Stranzenbach, R. Szepesi, A. Alberti-Violetti, S. and Felicity, E. Cerroni, L. Kempf, W. Whittaker, S. and Willemze, R. Kim, Y. Scarisbrick, J. J.

Abstract

Background The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) in patients with newly diagnosed mycosis fungoides (MF). Objectives To identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB) staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures. Methods In total, 395 newly diagnosed patients with early-stage MF (stage IA-IIA) were recruited from 41 centres in 17 countries between 1 January 2015 and 31 December 2018 following central clinicopathological review. Results The most common first-line therapy was skin-directed therapy (SDT) (322 cases, 81 center dot 5%), while a smaller percentage (44 cases, 11 center dot 1%) received systemic therapy. Expectant observation was used in 7 center dot 3%. In univariate analysis, the use of systemic therapy was significantly associated with higher clinical stage (IA, 6%; IB, 14%; IIA, 20%; IA-IB vs. IIA, P < 0 center dot 001), presence of plaques (T1a/T2a, 5%; T1b/T2b, 17%; P < 0 center dot 001), higher modified Severity Weighted Assessment Tool (> 10, 15%

Published
2021

18. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study

Author

Quaglino, P, Prince, HM, Cowan, R, Vermeer, M, Papadavid, E, Bagot, M, Servitjie, O, Berti, E, Guenova, E, Stadler, R, Querfeld, C, Busschots, AM, Hodak, E, Patsatsi, A, Sanches, J, Maule, M, Yoo, J, Kevin, M, Fava, P, Ribero, S, Zocchi, L, Rubatto, M, Fierro, MT, Wehkamp, U, Marshalko, M, Mitteldorf, C, Akilov, O, Ortiz-Romero, P, Estrach, T, Vakeva, L, Enz, PA, Wobser, M, Bayne, M, Jonak, C, Rubeta, M, Forbes, A, Bates, A, Battistella, M, Amel-Kashipaz, R, Vydianath, B, Combalia, A, Georgiou, E, Hauben, E, Hong, EK, Jost, M, Knobler, R, Amitay-Laish, I, Miyashiro, D, Cury-Martins, J, Martinez, X, Muniesa, C, Prag-Naveh, H, Stratigos, A, Nikolaou, V, Quint, K, Ram-Wolff, C, Rieger, K, Stranzenbach, R, Szepesi, A, Alberti-Violetti, S, Felicity, E, Cerroni, L, Kempf, W, Whittaker, S, Willemze, R, Kim, Y, Scarisbrick, JJ, Quaglino, P, Prince, HM, Cowan, R, Vermeer, M, Papadavid, E, Bagot, M, Servitjie, O, Berti, E, Guenova, E, Stadler, R, Querfeld, C, Busschots, AM, Hodak, E, Patsatsi, A, Sanches, J, Maule, M, Yoo, J, Kevin, M, Fava, P, Ribero, S, Zocchi, L, Rubatto, M, Fierro, MT, Wehkamp, U, Marshalko, M, Mitteldorf, C, Akilov, O, Ortiz-Romero, P, Estrach, T, Vakeva, L, Enz, PA, Wobser, M, Bayne, M, Jonak, C, Rubeta, M, Forbes, A, Bates, A, Battistella, M, Amel-Kashipaz, R, Vydianath, B, Combalia, A, Georgiou, E, Hauben, E, Hong, EK, Jost, M, Knobler, R, Amitay-Laish, I, Miyashiro, D, Cury-Martins, J, Martinez, X, Muniesa, C, Prag-Naveh, H, Stratigos, A, Nikolaou, V, Quint, K, Ram-Wolff, C, Rieger, K, Stranzenbach, R, Szepesi, A, Alberti-Violetti, S, Felicity, E, Cerroni, L, Kempf, W, Whittaker, S, Willemze, R, Kim, Y, and Scarisbrick, JJ

Abstract

BACKGROUND: The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) in patients with newly diagnosed mycosis fungoides (MF). OBJECTIVES: To identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB) staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures. METHODS: In total, 395 newly diagnosed patients with early-stage MF (stage IA-IIA) were recruited from 41 centres in 17 countries between 1 January 2015 and 31 December 2018 following central clinicopathological review. RESULTS: The most common first-line therapy was skin-directed therapy (SDT) (322 cases, 81·5%), while a smaller percentage (44 cases, 11·1%) received systemic therapy. Expectant observation was used in 7·3%. In univariate analysis, the use of systemic therapy was significantly associated with higher clinical stage (IA, 6%; IB, 14%; IIA, 20%; IA-IB vs. IIA, P < 0·001), presence of plaques (T1a/T2a, 5%; T1b/T2b, 17%; P < 0·001), higher modified Severity Weighted Assessment Tool (> 10, 15%; ≤ 10, 7%; P = 0·01) and folliculotropic MF (FMF) (24% vs. 12%, P = 0·001). Multivariate analysis demonstrated significant associations with the presence of plaques (T1b/T2b vs. T1a/T2a, odds ratio 3·07) and FMF (odds ratio 2·83). The overall response rate (ORR) to first-line SDT was 73%, while the ORR to first-line systemic treatments was lower (57%) (P = 0·027). Health-related QoL improved significantly both in patients with responsive disease and in those with stable disease. CONCLUSIONS: Disease characteristics such as presence of plaques and FMF influence physician treatment choices, and SDT was superior to systemic therapy even in patients with such disease characteristics. Consequently, future treatment guidelines for early-stage MF need to address these issues.

Published
2021

19. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study

Author

Hodak, E, Sherman, S, Papadavid, E, Bagot, M, Querfeld, C, Quaglino, P, Prince, HM, Ortiz-Romero, PL, Stadler, R, Knobler, R, Guenova, E, Estrach, T, Patsatsi, A, Leshem, YA, Prague-Naveh, H, Berti, E, Alberti-Violetti, S, Cowan, R, Jonak, C, Nikolaou, V, Mitteldorf, C, Akilov, O, Geskin, L, Matin, R, Beylot-Barry, M, Vakeva, L, Sanches, JA, Servitje, O, Weatherhead, S, Wobser, M, Yoo, J, Bayne, M, Bates, A, Dunnill, G, Marschalko, M, Buschots, AM, Wehkamp, U, Evison, F, Hong, E, Amitay-Laish, I, Stranzenbach, R, Vermeer, M, Willemze, R, Kempf, W, Cerroni, L, Whittaker, S, Kim, YH, Scarisbrick, JJ, Hodak, E, Sherman, S, Papadavid, E, Bagot, M, Querfeld, C, Quaglino, P, Prince, HM, Ortiz-Romero, PL, Stadler, R, Knobler, R, Guenova, E, Estrach, T, Patsatsi, A, Leshem, YA, Prague-Naveh, H, Berti, E, Alberti-Violetti, S, Cowan, R, Jonak, C, Nikolaou, V, Mitteldorf, C, Akilov, O, Geskin, L, Matin, R, Beylot-Barry, M, Vakeva, L, Sanches, JA, Servitje, O, Weatherhead, S, Wobser, M, Yoo, J, Bayne, M, Bates, A, Dunnill, G, Marschalko, M, Buschots, AM, Wehkamp, U, Evison, F, Hong, E, Amitay-Laish, I, Stranzenbach, R, Vermeer, M, Willemze, R, Kempf, W, Cerroni, L, Whittaker, S, Kim, YH, and Scarisbrick, JJ

Abstract

BACKGROUND: Early-stage mycosis fungoides (MF) includes involvement of dermatopathic lymph nodes (LNs) or early lymphomatous LNs. There is a lack of unanimity among current guidelines regarding the indications for initial staging imaging in early-stage presentation of MF in the absence of enlarged palpable LNs. OBJECTIVES: To investigate how often imaging is performed in patients with early-stage presentation of MF, to assess the yield of LN imaging, and to determine what disease characteristics promoted imaging. METHODS: A review of clinicopathologically confirmed newly diagnosed patients with cutaneous patch/plaque (T1/T2) MF from PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) data. RESULTS: PROCLIPI enrolled 375 patients with stage T1/T2 MF: 304 with classical MF and 71 with folliculotropic MF. Imaging was performed in 169 patients (45%): 83 with computed tomography, 18 with positron emission tomography-computed tomography and 68 with ultrasound. Only nine of these (5%) had palpable enlarged (≥ 15 mm) LNs, with an over-representation of plaques, irrespectively of the 10% body surface area cutoff that distinguishes T1 from T2. Folliculotropic MF was not more frequently imaged than classical MF. Radiologically enlarged LNs (≥ 15 mm) were detected in 30 patients (18%); only seven had clinical lymphadenopathy. On multivariate analysis, plaque presentation was the sole parameter significantly associated with radiologically enlarged LNs. Imaging of only clinically enlarged LNs upstaged 4% of patients (seven of 169) to at least IIA, whereas nonselective imaging upstaged another 14% (24 of 169). LN biopsy, performed in eight of 30 patients, identified N3 (extensive lymphomatous involvement) in two and N1 (dermatopathic changes) in six. CONCLUSIONS: Physical examination was a poor determinant of LN enlargement or involvement. Presence of plaques was associated with a significant increase in identification of enlarged or involved LNs in patients w

Published
2021

20. Treatment of early‐stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*

Author

Quaglino, P., primary, Prince, H.M., additional, Cowan, R., additional, Vermeer, M., additional, Papadavid, E., additional, Bagot, M., additional, Servitjie, O., additional, Berti, E., additional, Guenova, E., additional, Stadler, R., additional, Querfeld, C., additional, Busschots, A.M., additional, Hodak, E., additional, Patsatsi, A., additional, Sanches, J., additional, Maule, M., additional, Yoo, J., additional, Kevin, M., additional, Fava, P., additional, Ribero, S., additional, Zocchi, L., additional, Rubatto, M., additional, Fierro, M.T., additional, Wehkamp, U., additional, Marshalko, M., additional, Mitteldorf, C., additional, Akilov, O., additional, Ortiz‐Romero, P., additional, Estrach, T., additional, Vakeva, L., additional, Enz, P.A., additional, Wobser, M., additional, Bayne, M., additional, Jonak, C., additional, Rubeta, M., additional, Forbes, A., additional, Bates, A., additional, Battistella, M., additional, Amel‐Kashipaz, R., additional, Vydianath, B., additional, Combalia, A., additional, Georgiou, E., additional, Hauben, E., additional, Hong, E.K., additional, Jost, M., additional, Knobler, R., additional, Amitay‐Laish, I., additional, Miyashiro, D., additional, Cury‐Martins, J., additional, Martinez, X., additional, Muniesa, C., additional, Prag‐Naveh, H., additional, Stratigos, A., additional, Nikolaou, V., additional, Quint, K., additional, Ram‐Wolff, C., additional, Rieger, K., additional, Stranzenbach, R., additional, Szepesi, Á., additional, Alberti‐Violetti, S., additional, Felicity, E., additional, Cerroni, L., additional, Kempf, W., additional, Whittaker, S., additional, Willemze, R., additional, Kim, Y., additional, and Scarisbrick, J.J., additional

Published
2021
Full Text
View/download PDF

25. Primary cutaneous peripheral T‐cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico‐pathological and prognostic features

Author

Kempf, W., primary, Mitteldorf, C., additional, Battistella, M., additional, Willemze, R., additional, Cerroni, L., additional, Santucci, M., additional, Geissinger, E., additional, Jansen, P., additional, Vermeer, M.H., additional, Marschalko, M., additional, Papadavid, E., additional, Piris, M.A., additional, Ortiz‐Romero, P.L., additional, Novelli, M., additional, Paulli, M., additional, Quaglino, P., additional, Ranki, A., additional, Rodríguez Peralto, J.L., additional, Wobser, M., additional, Auschra, B., additional, and Robson, A., additional

Published
2020
Full Text
View/download PDF

27. 样肉芽肿和 Sézary 综合征患者生活质量研究

Author

Molloy, K., primary, Jonak, C., additional, Sherida, F.J., additional, Woei‐A‐Ji, H., additional, Guenova, E., additional, Busschots, A.M., additional, Bervoets, A., additional, Hauben, E., additional, Knobler, R., additional, Porkert, S., additional, Fassnacht, C., additional, Cowan, R., additional, Papadavid, E., additional, Beylot‐Barry, M., additional, Berti, E., additional, Alberti Violetti, S., additional, Estrach, T., additional, Matin, R., additional, Akilov, O., additional, Vakeva, L., additional, Prince, M., additional, Bates, A., additional, Bayne, M., additional, Wachsmuch, R., additional, Wehkamp, U., additional, Marschalko, M., additional, Servitje, O., additional, Turner, D., additional, Weatherhead, S., additional, Wobser, M., additional, Sanches, J.A., additional, McKay, P., additional, Klemke, D., additional, Peng, C., additional, Howles, A., additional, Yoo, J., additional, Evison, F., additional, and Scarisbrick, J., additional

Published
2020
Full Text
View/download PDF

28. A study of quality of life in people with mycosis fungoides and Sézary syndrome

Author

Molloy, K., primary, Jonak, C., additional, Sherida, F.J., additional, Woei‐A‐Ji, H., additional, Guenova, E., additional, Busschots, A.M., additional, Bervoets, A., additional, Hauben, E., additional, Knobler, R., additional, Porkert, S., additional, Fassnacht, C., additional, Cowan, R., additional, Papadavid, E., additional, Beylot‐Barry, M., additional, Berti, E., additional, Alberti Violetti, S., additional, Estrach, T., additional, Matin, R., additional, Akilov, O., additional, Vakeva, L., additional, Prince, M., additional, Bates, A., additional, Bayne, M., additional, Wachsmuch, R., additional, Wehkamp, U., additional, Marschalko, M., additional, Servitje, O., additional, Turner, D., additional, Weatherhead, S., additional, Wobser, M., additional, Sanches, J.A., additional, McKay, P., additional, Klemke, D., additional, Peng, C., additional, Howles, A., additional, Yoo, J., additional, Evison, F., additional, and Scarisbrick, J., additional

Published
2020
Full Text
View/download PDF

37. An overall response in skin is associated with improved HRQoL in patients with MF/SS enrolled in the PROCLIPI study

Author

Molloy, K. Jonak, C. Sherida, F. J. Woei-A-Ji, H. and Guenova, E. Busschots, A. M. Bervoets, A. Hauben, E. and Knobler, R. Porkert, S. Fassnacht, C. Cowan, R. and Papadavid, E. Beylot-Barry, M. Berti, E. Violetti, S. Alberti Estrach, T. Matin, R. Akilov, O. Vakeva, L. and Prince, M. Bates, A. Bayne, M. Wachsmuch, R. Wehkamp, U. and Marschalko, M. Servitje, O. Turner, D. Weatherhead, S. and Wobser, M. Sanches, J. Antonio Mckay, P. Klemke, D. and Howles, A. Yoo, J. Evison, F. Scarisbrick, J.

Published
2019

39. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index ( PROCLIPI ) study

Author

Molloy, K., primary, Jonak, C., additional, Woei‐A‐Jin, F.J.S.H., additional, Guenova, E., additional, Busschots, A.M., additional, Bervoets, A., additional, Hauben, E., additional, Knobler, R., additional, Porkert, S., additional, Fassnacht, C., additional, Cowan, R., additional, Papadavid, E., additional, Beylot‐Barry, M., additional, Berti, E., additional, Alberti Violetti, S., additional, Estrach, T., additional, Matin, R., additional, Akilov, O., additional, Vakeva, L., additional, Prince, M., additional, Bates, A., additional, Bayne, M., additional, Wachsmuch, R., additional, Wehkamp, U., additional, Marschalko, M., additional, Servitje, O., additional, Turner, D., additional, Weatherhead, S., additional, Wobser, M., additional, Sanches, J.A., additional, McKay, P., additional, Klemke, D., additional, Peng, C., additional, Howles, A., additional, Yoo, J., additional, Evison, F., additional, and Scarisbrick, J., additional

Published
2019
Full Text
View/download PDF

42. Extended surgical safety margins and ulceration are associated with an improved prognosis in pleomorphic dermal sarcomas

Author

Persa, O. D., Loquai, C., Wobser, M., Baltaci, M., Dengler, S., Kreuter, A., Volz, A., Laimer, M., Emberger, M., Doerler, M., Mauch, C., Helbig, D., Persa, O. D., Loquai, C., Wobser, M., Baltaci, M., Dengler, S., Kreuter, A., Volz, A., Laimer, M., Emberger, M., Doerler, M., Mauch, C., and Helbig, D.

Abstract

Background Pleomorphic dermal sarcomas (PDS) are frequent UV-induced sarcomas of the skin of intermediate grade malignant potential. Despite the fact that PDS have a noteworthy potential to recur (up to 28%) as well as to metastasize (up to 20%), there are no specific clinical guidelines with respect to follow-up these patients. Moreover, little is known about clinical, histological or molecular prognostic factors in PDS. Objective The aim of the present study was to identify risk factors to predict relapse in a large multicentre sample cohort of PDS which could aid to optimize personalized treatment recommendations regarding surgical safety margins and adjuvant radiotherapy. Methods Patients with a diagnosis of PDS were selected from nine European institutions based on the histopathologic criteria described by Fletcher. Clinicopathologic and follow-up data were collected and statistically analysed calculating univariate hazard ratios with 95% confidence intervals by use of the Cox proportional-hazards model and a significance level of P < 0.05. Patients with an incomplete excision of the tumour were excluded. Results Univariate Cox regression analysis of possible prognostic factors for progression-free survival (PFS) performed in 92 patients revealed that an excision margin of PDS [hazard ratio 4.478 (95% CI 1.536-13.055), P = 0.006]. Ulceration of the tumour was associated with a significantly better prognosis [0.396 (0.174-0.904), P = 0.028] whereas adjuvant radiotherapy did not reach statistical significance to improve prognosis in patients with PDS [0.775 (0.231-2.593), P = 0.679]. Gender, age, immunosuppression, intratumoural necrosis, tumour location, vertical thickness or horizontal diameter did not significantly influence PFS in PDS. Conclusion We identified surgical safety margins of PDS. These findings may be implemented into both the primary treatment as well as the further monitoring of patients with PDS.

Published
2019

43. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients

Author

Scarisbrick, JJ, Quaglino, P, Prince, HM, Papadavid, E, Hodak, E, Bagot, M, Servitje, O, Berti, E, Ortiz-Romero, P, Stadler, R, Patsatsi, A, Knobler, R, Guenova, E, Child, F, Whittaker, S, Nikolaou, V, Tomasini, C, Amitay, I, Prag Naveh, H, Ram-Wolff, C, Battistella, M, Alberti-Violetti, S, Stranzenbach, R, Gargallo, V, Muniesa, C, Koletsa, T, Jonak, C, Porkert, S, Mitteldorf, C, Estrach, T, Combalia, A, Marschalko, M, Csomor, J, Szepesi, A, Cozzio, A, Dummer, R, Pimpinelli, N, Grandi, V, Beylot-Barry, M, Pham-Ledard, A, Wobser, M, Geissinger, E, Wehkamp, U, Weichenthal, M, Cowan, R, Parry, E, Harris, J, Wachsmuth, R, Turner, D, Bates, A, Healy, E, Trautinger, F, Latzka, J, Yoo, J, Vydianath, B, Amel-Kashipaz, R, Marinos, L, Oikonomidi, A, Stratigos, A, Vignon-Pennamen, M-D, Climent, F, Gonzalez-Barca, E, Georgiou, E, Senetta, R, Zinzani, P, Vakeva, L, Ranki, A, Busschots, A-M, Hauben, E, Bervoets, A, Woei-A-Jin, FJSH, Matin, R, Collins, G, Weatherhead, S, Frew, J, Bayne, M, Dunnill, G, McKay, P, Arumainathan, A, Azurdia, R, Benstead, K, Twigger, R, Rieger, K, Brown, R, Sanches, JA, Miyashiro, D, Akilov, O, McCann, S, Sahi, H, Damasco, FM, Querfeld, C, Folkes, A, Bur, C, Klemke, C-D, Enz, P, Pujol, R, Quint, K, Geskin, L, Hong, E, Evison, F, Vermeer, M, Cerroni, L, Kempf, W, Kim, Y, Willemze, R, Scarisbrick, JJ, Quaglino, P, Prince, HM, Papadavid, E, Hodak, E, Bagot, M, Servitje, O, Berti, E, Ortiz-Romero, P, Stadler, R, Patsatsi, A, Knobler, R, Guenova, E, Child, F, Whittaker, S, Nikolaou, V, Tomasini, C, Amitay, I, Prag Naveh, H, Ram-Wolff, C, Battistella, M, Alberti-Violetti, S, Stranzenbach, R, Gargallo, V, Muniesa, C, Koletsa, T, Jonak, C, Porkert, S, Mitteldorf, C, Estrach, T, Combalia, A, Marschalko, M, Csomor, J, Szepesi, A, Cozzio, A, Dummer, R, Pimpinelli, N, Grandi, V, Beylot-Barry, M, Pham-Ledard, A, Wobser, M, Geissinger, E, Wehkamp, U, Weichenthal, M, Cowan, R, Parry, E, Harris, J, Wachsmuth, R, Turner, D, Bates, A, Healy, E, Trautinger, F, Latzka, J, Yoo, J, Vydianath, B, Amel-Kashipaz, R, Marinos, L, Oikonomidi, A, Stratigos, A, Vignon-Pennamen, M-D, Climent, F, Gonzalez-Barca, E, Georgiou, E, Senetta, R, Zinzani, P, Vakeva, L, Ranki, A, Busschots, A-M, Hauben, E, Bervoets, A, Woei-A-Jin, FJSH, Matin, R, Collins, G, Weatherhead, S, Frew, J, Bayne, M, Dunnill, G, McKay, P, Arumainathan, A, Azurdia, R, Benstead, K, Twigger, R, Rieger, K, Brown, R, Sanches, JA, Miyashiro, D, Akilov, O, McCann, S, Sahi, H, Damasco, FM, Querfeld, C, Folkes, A, Bur, C, Klemke, C-D, Enz, P, Pujol, R, Quint, K, Geskin, L, Hong, E, Evison, F, Vermeer, M, Cerroni, L, Kempf, W, Kim, Y, and Willemze, R

Abstract

BACKGROUND: Survival in mycosis fungoides (MF) is varied and may be poor. The PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) study is a web-based data collection system for early-stage MF with legal data-sharing agreements permitting international collaboration in a rare cancer with complex pathology. Clinicopathological data must be 100% complete and in-built intelligence in the database system ensures accurate staging. OBJECTIVES: To develop a prognostic index for MF. METHODS: Predefined datasets for clinical, haematological, radiological, immunohistochemical, genotypic, treatment and quality of life are collected at first diagnosis of MF and annually to test against survival. Biobanked tissue samples are recorded within a Federated Biobank for translational studies. RESULTS: In total, 430 patients were enrolled from 29 centres in 15 countries spanning five continents. Altogether, 348 were confirmed as having early-stage MF at central review. The majority had classical MF (81·6%) with a CD4 phenotype (88·2%). Folliculotropic MF was diagnosed in 17·8%. Most presented with stage I (IA: 49·4%; IB: 42·8%), but 7·8% presented with enlarged lymph nodes (stage IIA). A diagnostic delay between first symptom development and initial diagnosis was frequent [85·6%; median delay 36 months (interquartile range 12-90)]. This highlights the difficulties in accurate diagnosis, which includes lack of a singular diagnostic test for MF. CONCLUSIONS: This confirmed early-stage MF cohort is being followed-up to identify prognostic factors, which may allow better management and improve survival by identifying patients at risk of disease progression. This study design is a useful model for collaboration in other rare diseases, especially where pathological diagnosis can be complex.

Published
2019

44. Primary cutaneous peripheral T‐cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico‐pathological and prognostic features

Author

Kempf, W., Mitteldorf, C., Battistella, M., Willemze, R., Cerroni, L., Santucci, M., Geissinger, E., Jansen, P., Vermeer, M.H., Marschalko, M., Papadavid, E., Piris, M.A., Ortiz‐Romero, P.L., Novelli, M., Paulli, M., Quaglino, P., Ranki, A., Rodríguez Peralto, J.L., Wobser, M., and Auschra, B.

Subjects
CUTANEOUS T-cell lymphoma, PROGNOSIS, ORGANIZATIONAL research, CANCER treatment, LYMPHOMAS, CANCER research
Abstract

Background: Cutaneous peripheral T‐cell lymphoma, not otherwise specified (PTL NOS) is an aggressive, but poorly characterized neoplasm. Objectives: The European Organization for Research and Treatment of Cancer cutaneous lymphoma taskforce (EORTC CLTF) investigated 33 biopsies of 30 patients with primary cutaneous PTL NOS to analyse their clinical, histological, immunophenotypic features and outcome. Methods: Retrospective analysis of clinical data and histopathological features by an expert panel. Results: Cutaneous PTL NOS manifested clinically either with solitary or disseminated rapidly grown ulcerated tumours or disseminated papulo‐nodular lesions. Histologically, a mostly diffuse or nodular infiltrate in the dermis and often extending into the subcutis was found. Epidermotropism was rarely present and only mild and focal. Unusual phenotypes were frequent, e.g. CD3+/CD4−/CD8− and CD3+/CD4+/CD8+. Moreover, 18% of the cases exhibited an aberrant expression of the B‐cell marker CD20 by the tumour cells. All solitary tumours were located on the limbs and presented a high expression of GATA‐3 but this did not correlate with outcome and therefore could not serve as a prognostic factor. The prognosis was shown to be generally poor with 10 of 30 patients (33%) dying of lymphoma within the follow‐up of 36 months (mean value; range 3–144). The survival rates were 61% after 3 years (CI, 43–85%) and 54% after 5 years (CI, 36–81%). Small to medium‐sized morphology of tumour cells was associated with a better outcome than medium to large or large tumour cells. Age, gender, clinical stage, CD4/CD8 phenotype and GATA‐3 expression were not associated with prognosis. Chemotherapy was the most common treatment modality, but surgical excision and/or radiotherapy may represent an appropriate first‐line treatment for solitary lesions. Conclusions: Cutaneous PTL NOS shows an aggressive course in most patients independent of initial presentation, age and phenotype. Cytomorphology was identified as a prognostic factor. The data indicate a need for more effective treatment modalities in PTL NOS. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

46. An overall response in skin is associated with improved HRQoL in patients with MF/SS enrolled in the PROCLIPI study

Author

Molloy, K., primary, Jonak, C., additional, Sherida, F.J., additional, Woei-A-Ji, H., additional, Guenova, E., additional, Busschots, A.M., additional, Bervoets, A., additional, Hauben, E., additional, Knobler, R., additional, Porkert, S., additional, Fassnacht, C., additional, Cowan, R., additional, Papadavid, E., additional, Beylot-Barry, M., additional, Berti, E., additional, Alberti Violetti, S., additional, Estrach, T., additional, Matin, R., additional, Akilov, O., additional, Vakeva, L., additional, Prince, M., additional, Bates, A., additional, Bayne, M., additional, Wachsmuch, R., additional, Wehkamp, U., additional, Marschalko, M., additional, Servitje, O., additional, Turner, D., additional, Weatherhead, S., additional, Wobser, M., additional, Antonio Sanches, J., additional, McKay, P., additional, Klemke, D., additional, Howles, A., additional, Yoo, J., additional, Evison, F., additional, and Scarisbrick, J., additional

Published
2019
Full Text
View/download PDF

49. The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients

Author

Scarisbrick, J.J., primary, Quaglino, P., additional, Prince, H.M., additional, Papadavid, E., additional, Hodak, E., additional, Bagot, M., additional, Servitje, O., additional, Berti, E., additional, Ortiz‐Romero, P., additional, Stadler, R., additional, Patsatsi, A., additional, Knobler, R., additional, Guenova, E., additional, Child, F., additional, Whittaker, S., additional, Nikolaou, V., additional, Tomasini, C., additional, Amitay, I., additional, Prag Naveh, H., additional, Ram‐Wolff, C., additional, Battistella, M, additional, Alberti‐Violetti, S., additional, Stranzenbach, R., additional, Gargallo, V., additional, Muniesa, C., additional, Koletsa, T., additional, Jonak, C., additional, Porkert, S., additional, Mitteldorf, C., additional, Estrach, T., additional, Combalia, A., additional, Marschalko, M., additional, Csomor, J., additional, Szepesi, A., additional, Cozzio, A., additional, Dummer, R., additional, Pimpinelli, N., additional, Grandi, V., additional, Beylot‐Barry, M., additional, Pham‐Ledard, A., additional, Wobser, M., additional, Geissinger, E., additional, Wehkamp, U., additional, Weichenthal, M., additional, Cowan, R., additional, Parry, E., additional, Harris, J., additional, Wachsmuth, R., additional, Turner, D., additional, Bates, A., additional, Healy, E., additional, Trautinger, F., additional, Latzka, J., additional, Yoo, J., additional, Vydianath, B., additional, Amel‐Kashipaz, R., additional, Marinos, L., additional, Oikonomidi, A., additional, Stratigos, A., additional, Vignon‐Pennamen, M.‐D., additional, Battistella, M., additional, Climent, F., additional, Gonzalez‐Barca, E., additional, Georgiou, E., additional, Senetta, R., additional, Zinzani, P., additional, Vakeva, L., additional, Ranki, A., additional, Busschots, A.‐M., additional, Hauben, E., additional, Bervoets, A., additional, Woei‐A‐Jin, F.J.S.H., additional, Matin, R., additional, Collins, G., additional, Weatherhead, S., additional, Frew, J., additional, Bayne, M., additional, Dunnill, G., additional, McKay, P., additional, Arumainathan, A., additional, Azurdia, R., additional, Benstead, K., additional, Twigger, R., additional, Rieger, K., additional, Brown, R., additional, Sanches, J.A., additional, Miyashiro, D., additional, Akilov, O., additional, McCann, S., additional, Sahi, H., additional, Damasco, F.M., additional, Querfeld, C., additional, Folkes, A., additional, Bur, C., additional, Klemke, C.‐D., additional, Enz, P., additional, Pujol, R., additional, Quint, K., additional, Geskin, L., additional, Hong, E., additional, Evison, F., additional, Vermeer, M., additional, Cerroni, L., additional, Kempf, W., additional, Kim, Y., additional, and Willemze, R., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results